HRP20202024T1 - Cd3-vežuća domena - Google Patents
Cd3-vežuća domena Download PDFInfo
- Publication number
- HRP20202024T1 HRP20202024T1 HRP20202024TT HRP20202024T HRP20202024T1 HR P20202024 T1 HRP20202024 T1 HR P20202024T1 HR P20202024T T HRP20202024T T HR P20202024TT HR P20202024 T HRP20202024 T HR P20202024T HR P20202024 T1 HRP20202024 T1 HR P20202024T1
- Authority
- HR
- Croatia
- Prior art keywords
- binding protein
- antigen
- antigen binding
- domain
- seq
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Gyroscopes (AREA)
- Optical Communication System (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2014/002177 WO2015018527A1 (en) | 2013-08-07 | 2014-08-07 | ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII |
| EP15154772.6A EP2982693A1 (en) | 2014-08-07 | 2015-02-11 | CD3 binding domain |
| EP15756850.2A EP3177646B1 (en) | 2014-08-07 | 2015-08-05 | Cd3 binding domain |
| PCT/EP2015/068070 WO2016020444A1 (en) | 2014-08-07 | 2015-08-05 | Cd3 binding domain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20202024T1 true HRP20202024T1 (hr) | 2021-02-19 |
Family
ID=52468915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20202024TT HRP20202024T1 (hr) | 2014-08-07 | 2015-08-05 | Cd3-vežuća domena |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10066015B2 (enExample) |
| EP (2) | EP2982693A1 (enExample) |
| JP (1) | JP6669722B2 (enExample) |
| CN (1) | CN107001468B (enExample) |
| AU (1) | AU2015299039B2 (enExample) |
| BR (1) | BR112017002422B1 (enExample) |
| CA (1) | CA2957462C (enExample) |
| DK (1) | DK3177646T3 (enExample) |
| HR (1) | HRP20202024T1 (enExample) |
| HU (1) | HUE051919T2 (enExample) |
| LT (1) | LT3177646T (enExample) |
| RU (1) | RU2742691C2 (enExample) |
| SI (1) | SI3177646T1 (enExample) |
| WO (1) | WO2016020444A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105873953A (zh) | 2013-11-04 | 2016-08-17 | 格兰马克药品股份有限公司 | 重靶向t细胞的异源二聚免疫球蛋白的产生 |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| IL313608A (en) | 2015-12-09 | 2024-08-01 | Hoffmann La Roche | Antibody against CD20 type II to reduce the formation of antibodies against drugs |
| EP3411407B1 (en) | 2016-02-05 | 2024-04-03 | Orionis Biosciences BV | Bispecific signaling agents and uses thereof |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| AU2018276419A1 (en) | 2016-06-02 | 2019-10-17 | F. Hoffmann-La Roche Ag | Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| EP3576765B1 (en) | 2017-02-06 | 2025-07-16 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| JP7556687B2 (ja) | 2017-02-24 | 2024-09-26 | 中外製薬株式会社 | 薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法 |
| EP3366704A1 (en) | 2017-02-28 | 2018-08-29 | Affimed GmbH | Antibodies specific for mmp1/hla-a2 complex |
| CN110770255B (zh) | 2017-04-11 | 2025-07-01 | 因荷布瑞克斯生物科学公司 | 具有受限cd3结合的多特异性多肽构建体及其使用方法 |
| EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| WO2018224441A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| KR102651965B1 (ko) * | 2017-06-05 | 2024-03-28 | 누맙 세러퓨틱스 아게 | 신규 항 cd3 항체 |
| WO2019034580A1 (en) | 2017-08-14 | 2019-02-21 | Morphosys Ag | HUMANIZED ANTIBODIES FOR CD3 |
| KR101973060B1 (ko) | 2017-10-20 | 2019-04-26 | 주식회사 녹십자 | 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
| EP3502140A1 (en) * | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
| US20200399373A1 (en) | 2018-02-14 | 2020-12-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule and combination |
| CN120399075A (zh) * | 2018-03-14 | 2025-08-01 | 诺维莫尼公司 | 抗-CD3ε抗体及其应用方法 |
| MX2020010638A (es) | 2018-04-11 | 2021-01-08 | Inhibrx Inc | Constructos de polipeptidos multiespecificos que tienen union a cd3 restringida y metodos y usos relacionados. |
| HRP20250621T1 (hr) * | 2018-05-24 | 2025-07-18 | Janssen Biotech, Inc. | Protutijela usmjerena na cd3 i njihove primjene |
| JP7651450B2 (ja) * | 2018-07-24 | 2025-03-26 | インヒブルクス バイオサイエンシズ インコーポレイテッド | 制約されたｃｄ３結合ドメインおよび受容体結合領域を含有する多重特異性ポリペプチド構築物ならびにそれを使用する方法 |
| US11578127B2 (en) | 2018-08-23 | 2023-02-14 | Regeneron Pharmaceuticals, Inc. | Anti-Fc epsilon-R1 alpha (FcεR1α) antibodies, bispecific antigen-binding molecules that bind FcεR1α and CD3, and uses thereof |
| CA3115089A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| AU2019439345B2 (en) * | 2019-03-29 | 2024-08-08 | Green Cross Corporation | Fusion protein comprising anti-mesothelin antibody, anti-CD3 antibody or anti-EGFR antibody, bispecific or trispecific antibody comprising same, and uses thereof |
| TWI888487B (zh) * | 2020-02-14 | 2025-07-01 | 日商協和麒麟股份有限公司 | 與ｃｄ３結合之雙特異性抗體 |
| CR20220594A (es) | 2020-05-27 | 2023-01-17 | Janssen Biotech Inc | Proteins comprising cd3 antigen binding domains and uses thereof |
| WO2022068809A1 (zh) * | 2020-09-29 | 2022-04-07 | 信达生物制药(苏州)有限公司 | 抗cd3抗体以及其用途 |
| AU2021443863A1 (en) | 2021-04-30 | 2023-10-26 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
| AU2021443318A1 (en) | 2021-04-30 | 2023-09-07 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| JP2024523033A (ja) | 2021-06-17 | 2024-06-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規の三重特異的結合分子 |
| KR20240130125A (ko) | 2021-12-31 | 2024-08-28 | 카이노 바이오테크놀로지 컴퍼니 리미티드 | 항-gprc5d 항체 및 그의 응용 |
| WO2023125729A1 (zh) * | 2021-12-31 | 2023-07-06 | 康源博创生物科技(北京)有限公司 | 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用 |
| CN119584984A (zh) | 2022-03-23 | 2025-03-07 | 豪夫迈·罗氏有限公司 | 抗cd20/抗cd3双特异性抗体与化学疗法的组合治疗 |
| CA3255366A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions based on bispecific anti-CD20/anti-CD3 antibodies and methods of use |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| WO2024152963A1 (zh) * | 2023-01-18 | 2024-07-25 | 贝达药业股份有限公司 | 抗cd3的人源化抗体及其应用 |
| WO2025224084A1 (en) | 2024-04-22 | 2025-10-30 | Engimmune Therapeutics Ag | Proteins comprising t cell receptor constant domains |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1297090B1 (it) * | 1997-12-01 | 1999-08-03 | Barbara Ensoli | Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le |
| CN1927883B (zh) * | 1999-03-09 | 2011-09-21 | 津莫吉尼蒂克斯公司 | 新的细胞因子zalpha11配体 |
| EP1293514B1 (en) | 2001-09-14 | 2006-11-29 | Affimed Therapeutics AG | Multimeric single chain tandem Fv-antibodies |
| DK1716178T3 (da) | 2004-02-16 | 2010-09-20 | Micromet Ag | Mindre immunogene bindingsmolekyler |
| PT2612868T (pt) * | 2007-11-01 | 2018-10-24 | Astellas Pharma Inc | Ácidos nucleicos e polipéptidos imunosupressores |
| TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| WO2012133782A1 (ja) * | 2011-03-30 | 2012-10-04 | 中外製薬株式会社 | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 |
| UA115402C2 (uk) * | 2011-05-21 | 2017-10-25 | Макродженікс, Інк. | Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським |
| WO2014106004A2 (en) * | 2012-12-28 | 2014-07-03 | Abbvie, Inc. | High-throughput system and method for identifying antibodies having specific antigen binding activities |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US20140242077A1 (en) | 2013-01-23 | 2014-08-28 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| CA2920173C (en) * | 2013-08-07 | 2021-08-10 | Affimed Therapeutics Ag | Antibody binding sites specific for egfrviii |
| US9212225B1 (en) * | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
-
2015
- 2015-02-11 EP EP15154772.6A patent/EP2982693A1/en not_active Withdrawn
- 2015-08-05 SI SI201531457T patent/SI3177646T1/sl unknown
- 2015-08-05 WO PCT/EP2015/068070 patent/WO2016020444A1/en not_active Ceased
- 2015-08-05 EP EP15756850.2A patent/EP3177646B1/en active Active
- 2015-08-05 CN CN201580054757.1A patent/CN107001468B/zh active Active
- 2015-08-05 CA CA2957462A patent/CA2957462C/en active Active
- 2015-08-05 RU RU2017105120A patent/RU2742691C2/ru active
- 2015-08-05 DK DK15756850.2T patent/DK3177646T3/da active
- 2015-08-05 BR BR112017002422-5A patent/BR112017002422B1/pt active IP Right Grant
- 2015-08-05 LT LTEP15756850.2T patent/LT3177646T/lt unknown
- 2015-08-05 HU HUE15756850A patent/HUE051919T2/hu unknown
- 2015-08-05 JP JP2017506890A patent/JP6669722B2/ja active Active
- 2015-08-05 HR HRP20202024TT patent/HRP20202024T1/hr unknown
- 2015-08-05 AU AU2015299039A patent/AU2015299039B2/en active Active
- 2015-08-06 US US14/820,462 patent/US10066015B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017002422B1 (pt) | 2024-02-20 |
| JP2017529067A (ja) | 2017-10-05 |
| LT3177646T (lt) | 2021-01-11 |
| RU2017105120A (ru) | 2018-09-10 |
| RU2742691C2 (ru) | 2021-02-09 |
| CN107001468B (zh) | 2021-04-09 |
| AU2015299039B2 (en) | 2021-01-21 |
| RU2017105120A3 (enExample) | 2019-02-20 |
| CA2957462C (en) | 2023-10-17 |
| SI3177646T1 (sl) | 2021-04-30 |
| CN107001468A (zh) | 2017-08-01 |
| WO2016020444A1 (en) | 2016-02-11 |
| EP3177646A1 (en) | 2017-06-14 |
| JP6669722B2 (ja) | 2020-03-18 |
| US10066015B2 (en) | 2018-09-04 |
| US20160039934A1 (en) | 2016-02-11 |
| HUE051919T2 (hu) | 2021-04-28 |
| EP3177646B1 (en) | 2020-10-07 |
| EP2982693A1 (en) | 2016-02-10 |
| CA2957462A1 (en) | 2016-02-11 |
| DK3177646T3 (da) | 2020-12-07 |
| AU2015299039A1 (en) | 2017-03-02 |
| BR112017002422A2 (pt) | 2017-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20202024T1 (hr) | Cd3-vežuća domena | |
| JP2017529067A5 (enExample) | ||
| HRP20240767T1 (hr) | Cd3 vezujuća antitijela | |
| HRP20210739T1 (hr) | Molekule koje vežu antigen i sadrže trimer obitelji tnf liganada | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| RU2016106577A (ru) | САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII | |
| HRP20201156T1 (hr) | Zajednički laki lanci i postupci primjene | |
| JP2016536322A5 (enExample) | ||
| CO2018013500A2 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| HRP20191704T1 (hr) | Multispecifična protutijela | |
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| PE20220495A1 (es) | Receptores antigenicos quimericos y agentes de union dirigidos a dll3 | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| HRP20200164T1 (hr) | Bispecifična protutijela koja se vežu na cd38 i cd3 | |
| HRP20230060T1 (hr) | Antitijela protiv ox40 i njihova primjena | |
| HRP20240357T1 (hr) | Stanica | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| HRP20251127T1 (hr) | Humanizirana ili himerična cd3 protutijela | |
| HRP20191775T1 (hr) | Multispecifične konstrukcije antitijela | |
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| JP2019508444A5 (enExample) | ||
| JP2016196468A5 (enExample) | ||
| FI3546572T3 (fi) | Cd19-spesifinen kimeerinen antigeenireseptori ja sen käyttötapoja | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| PE20181066A1 (es) | Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos |